SLAS2017 Scientific Podium Program Abstract Compendium

Podium presentations are organized into seven educational tracks. Podium abstracts and speaker information are organized first by track and then by session below.

To search for a specific speaker use the 'Find' functionality in your browser (usually Ctrl + F).

To view a complete schedule of podium presentations and schedule of events for SLAS2017 and to view speaker bios and photos, please visit the SLAS2017 Event Scheduler.

Advances in Bioanalytics, Biomarkers and Diagnostics Track

Track Chairs: Dieter Drexler, Bristol-Myers Squibb and Melanie Leveridge, GlaxoSmithKline

Label Free Bioanalytical Techniques for Hit Identification and Optimisation

Session Chair: Melanie Leveridge, GlaxoSmithKline

Targeted Biomarker Analysis

Session Chair: Dieter Drexler, BMS

Target Identification After Phenotypic Screening

Session Chair: Shaun McLoughlin, AbbVie Laboratories

Back to Top

Assay Development and Screening Track

Track Chairs: Cathy Tralau-Stewart, University of California, San Francisco and Edward Ainscow, Carrick Therapeutics

Biochemical and Biophysical Screening

Session Chair: Razvan Nutiu, NIBR

Phenotypic and High Content Screening Assays

Session Chair: Susanne Heynen-Genel, Sanford Burnham Prebys Medical Discovery Institute

Assay Platforms for Biologics

Session Chair: Rob Howes, AstraZeneca

Rational Screen Design

Session Chair: Edward Ainscow, GNF

Cellular Manipulation and Genome Editing in Screening Assay Design

Session Chair: Ralph Garippa, Memorial Sloan-Kettering Cancer Center

Screening the Undruggable

Session Chair: John Lazo, University of Virginia

Back to Top

Automation and High-Throughput Technologies

Track Chairs: Craig Schulz, Amgen and Taosheng Chen, St. Jude Children's Research Hospital

High Content and High Throughput Automation

Session Chair: Louis Scampavia, Scripps Florida; Department of Molecular Therapeutics

Screening Automation: Modular vs. Highly integrated systems

Session Chair: Paul Anderson, GNF

Automating Phenotypic and Target Based Discovery using Parallel Automated Approaches

Session Chair: Robin Felder, The University of Virginia

Using Physiologically-relevant Models for Automated Screens

Session Chair: Shane Horman, GNF (Novartis)

Automating Novel Analytical Tools for PKA, Drug-Drug Combination and Synergy Assays, Drug Repurposing

Session Chair: Wei Zheng, National Center for Advancing Translational Sciences, NIH

In-house Automation: Devices and Software Developed Internally

Session Chair: Rob Keyser, Calico Life Sciences

Back to Top

Cellular Technologies Track

Track Chairs: John Doench, the Broad Institute and Benjamin Haley, Genentech

Advances in Genome Editing Technologies

Session Chair: Gregory Davis, MIlliporeSigma

Development of Cellular Models for Phenotypic Screening

Session Chair: Joel Klappenbach, Merck & Co., Inc.

Genetic Screens for Target Discovery and Validation

Session Chair: Louis Staudt, National Cancer Institute

Back to Top

Data Analysis and Informatics Track

Track Chairs: Lenny Teytelman, and Margaret DiFilippo, Dotmatics

Let There Be Light: Informatics Approaches to Exploring the Dark Genome

Session Chair: Rajarshi Guha, NCATS

The Challenges and Benefits of Collaboration

Session Chair: Farida Kopti, Merck & Co

Enhancing Scientific Reproducibility and Reuse Through Better Workflow and Data Technologies

Session Chair: Timothy Gardner, Riffyn

Making Scientific Data 100x Easier to Use

Session Chair: Amy Kallmerten, Merck Research Labs

Informatics of Drug Design and Compound Life Cycle Management

Session Chair: Dmitry Lupyan, Schrodinger

The Digital Dark Hole: Handling Large-Scale Data for Use, Reuse, and Sharing

Session Chair: Laurie Goodman, GigaScience

Back to Top

Drug Target Strategies Track

Track Chairs: David Swinney, iRND3 and Chun-wa Chung, GlaxoSmithKline

Hard Targets — Success Through Collaborations

Session Chair: Chun-Wa Chung, GSK

Non-Traditional Modalities as Therapeutics

Session Chair: Stephen Hale, Ensemble Therapeutics

Uniting Phenotypic and Target-Based Drug Discovery

Session Chair: Fabien Vincent, Pfizer

Back to Top

Micro- and Nanotechnologies Track

Track Chairs: Sindy Tang, Stanford University and Andrew deMello, Institute for Chemical and Bioengineering

Digital and Droplet Microfluidics

Session Chair: Adam Abate, UCSF

Perspectives on Commercialization of Integrated Micro and Nanofluidic Devices

Session Chair: Sammy Datwani, Labcyte Inc.

Making Micro-Volume Biology Work: Tools, Techniques & Secrets

Session Chair: Daniel Sipes, GNF

Single Cell Analyses

Session Chair: Daniel Chiu, UW

Bioprinting: Multidimensional Microscale Cellular/Tissue Engineering

Session Chair: Markus Rimann, Zurich University of Applied Sciences

Microphysiological Systems

Session Chair: Dan Huh, Penn

Back to Top

Special Sessions

Panel Discussion: Whose Responsibility is Research Reproducibility?

Session Chairs: Lenny Teytelman, Protocols and Cathy Tralau-Stewart, Catalyst & Associate Professor Therapeutics (AJ), University of California San Francisco

Moderator: Richard Harris, NPR

Cathy Tralau-Stewart, Catalyst & Associate Professor Therapeutics (AJ), University of California San Francisco
Richard Neve, Gilead
Ivan Oransky, Retraction Watch
Tara Schwetz, National Institutes of Health
Elizabeth Iorns, Science Exchange
Veronique Kiermer, PLOS

There is a broad consensus among academic and industry researchers, funders, and the lung is arguably the most mechanically active organ in the human body that continually experiences dynamic tissue deformation and fluid flow throughout life. Various types of mechanical forces arising from this dynamic environment are essential to the homeostasis and physiological function of the respiratory system. Clinical evidence has suggested that abnormal alterations in the mechanics of the lung may play a causative role in many respiratory diseases. Research efforts to delineate the fundamentals of this significant clinical association, however, have been greatly hampered by the technical challenges of modeling complex changes in the structure and mechanical microenvironment of the respiratory tract during disease progression. Here we describe a novel microengineering strategy to tackle this long-standing, critical challenge in respiratory biology and medicine. This approach is based on microphysiological three-dimensional (3D) cell culture integrated with programmable actuation of soft elastomeric microstructures to emulate i) cellular heterogeneity and complex microarchitecture of native lung tissue and ii) disease-induced mechanical forces and resultant pathophysiological tissue distortion in the lung. Specifically, we have created a microengineered disease model that reconstitutes the constriction of conducting airways in the distal lung, which is a hallmark of obstructive lung diseases such as asthma and chronic obstructive pulmonary disease. As the first step to establish this model, we constructed a compartmentalized microfluidic device that enabled co-culture of primary human small airway epithelial cells, lung fibroblasts, and lung microvascular endothelial cells in a physiologically relevant spatial arrangement. Fabrication of this device was achieved by utilizing removable templates and surface tension-induced pinning effects to form an airway compartment enclosed by an extracellular matrix hydrogel scaffold that contained a perfusable microchannel. Cell culture in this system produced multilayered tissue constructs consisting of the small airway epithelium supported by the underlying stroma laden with fibroblasts and perfused through an endothelialized vascular tube. To mimic pathophysiological obstruction of small airways during disease, we integrated our cell culture platform with a microfabricated soft elastomeric actuator capable of converting pneumatic pressure into precisely controlled inflation of microchannel walls. Actuation of this component exerted compressive forces on the cell culture chamber and induced the microfluidic airway tissue to undergo 3D structural distortion reminiscent of airway constriction in vivo. Our small airway-on-a-chip represents a major advance in the development of new technologies to address the critical unmet need for human-relevant lung disease models. This system provides a novel platform to investigate how mechanical abnormalities contribute to disease processes in the distal airways that have recently emerged as a key player in the development and progression of various lung diseases. Our microengineered model has the potential for broad impact in pulmonary research and may play an integral role in improving our fundamental understanding of respiratory health and disease.stakeholders that increasing reproducibility of published research is an important goal. However, questions of who should be responsible for validating research results are tricky; industry and academia naturally diverge in answering these. Moreover, specific proposals for improving reproducibility are frequently contentious with fears of unintended consequences for the research enterprise. The goal of this panel is to have a conversation with both industry and academic perspectives on this challenging issue.

Regenerative Medicine: Next Generation Treatments

Session Chairs: Marcie Glicksman, Orig3n, Inc. and G. Sitta Sittampalam, NIH/NCATS

Back to Top